The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer. The bifunctional PD-L1/TGF-β inhibitor SHR-1701, in ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo. Ponsegromab (PF-06946860), a GDF-15 inhibitor, increased weight gain ...

22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers ...

Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer ...